Tirzepatide Works Just as Well and as Safely for Adults Over 65
Graded Moderate — post hoc analysis pooling seven Phase 3 randomized trials, yet adults 65 and older were an unplanned subgroup and the abstract reports no sample size.
- Design
- —
- Participants
- 3
- Duration
- —
- Funding
- Tirzepatide is made by Eli Lilly, which runs the SURMOUNT and SUMMIT trials.
This analysis suggests tirzepatide may be a reasonable weight option for older adults after weighing risks.
Tirzepatide is the popular GLP-1 weight loss drug also sold as Mounjaro and Zepbound. This look back at big trials found it helped adults over 65 lose weight and improve heart and blood sugar health. The benefits and side effects matched what younger adults saw, with no new risks for older bodies.
Conflict of Interest Disclosure: Tirzepatide is made by Eli Lilly, which runs the SURMOUNT and SUMMIT trials.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.
Related Studies
All researchOzempic-Style Drugs May Slow Biological Aging, Not Just Shrink Waistlines
GLP-1 drugs like semaglutide cut deaths and heart problems by more than their weight and blood sugar effects alone would explain.
Why Muscle Quality Matters So Much on GLP-1 Weight Loss Drugs
Drugs like Ozempic drop weight fast, but some of that loss is muscle, not just fat.
After 70, Staying Fit for Just One More Year Cut Heart Risk by 40%
Norwegian adults aged 70 to 77 had their actual oxygen uptake measured, not just guessed from a questionnaire.